NCT00275431 2011-06-29Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesAscenta TherapeuticsPhase 2 Completed50 enrolled
NCT00286780 2010-08-13Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic LeukemiaAscenta TherapeuticsPhase 2 Completed19 enrolled